As of 2015, three different PTH receptor agonists had been approved for treatment of women and men at high risk for osteoporosis or hypoparathyroidism. The three products achieved in 2015 combined sales of US$ 1.6 bln. The forthcoming patent expiry of teriparatide, the relatively easy production in E.coli and blockbuster sales make teriparatide an attractive target for biosimilar developments as well as for next generation improved PTH receptor agonist products.
This report evaluates current R&D activities for improved PTH-R agonists based on drug delivery solutions or molecular variation and on biosimilar products and developments in regulated and in less regulated markets. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage
About Competitor Analysis Series:
The Competitor Analysis Series delivers no-frills, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
2. Drug Delivery Solutions for PTH Receptor Agonists:
3. Molecularly-Defined Teriparatide Biosuperiors
4. Teriparatide Biosimilars
- In Regulated Markets
- In Less Regulated Markets
5. Corporate PTH Agonist Biosimilars & Biosuperiors R&D Pipelines